54 results about "Amitriptyline" patented technology

The invention is directed to a method for the treatment of a patient suffering from transient or short term insomnia. The claimed method comprises the administration of a compound selected from the group consisting of the pharmaceutically acceptable forms of doxepin, amitriptyline, trimipramine, trazodone and mixtures thereof in dosages ranging from about 0.5 to about 20.0 milligrams.

The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions. A priority GENOPROFILE is measured and directs the customization of a subsequent nutraceutical to act as a therapeutic modality. Specifically the treatment includes slow attenuation of the pain medication by incorporating orals (shakes, liquid beverages, pills, tablets, troche, ointments etc.), Intramuscular, Intravenous, intra-rectal and any form necessary to deliver a sufficient amount of an anti-craving and anti-stress nutraceutical. Moreover, the invention includes examples of novel analgesic ointments coupling Synaptamine and such analgesic and other anesthetic compounds including but not limited to Gabapentin, Ketamine, Baclofen, Ketoprofen, Amitriptyline, Lidocaine, Cyclobenzapine, Diclofenac, Menthol, Camphor and Capsaicin. The GENOPROFILE will be used to determine pain sensitivity Intolerance.

The invention mainly relates to the technical field of planting, and discloses a handling method of accelerating germination of a seed of fructus lycii. The processing method comprises the steps of seed soaking, seed drying, seed dressing and germination acceleration, and soil preparation and seed sowing. According to the handling method of accelerating germination of seed of fructus lycii, the method is simple, the bud ratio is 98%, time for germination is shortened to 4-5 days after the sowing, plant efficiency is obviously improved, and economic income is improved by 16.2%; the seed of fructus lycii is subjected to soaking through an amitriptyline solution, nutritional contents are provided, not only anti-microbial and insect killing effects are achieved, seed coat softening is also promoted, entering of nutritients and moisture are accelerated, and seed germination is promoted; after the seed is subjected to drying and surface skin moisture reducing, seed germ vigour is promoted at high temperature, stress resistance is improved, and germination rate is improved; bactericide is added into the dried seed, wherein the bactericide is extracted from pure plants, and can the bactericide can not only prevent bacteria and kill insects, but can also provide nutrients necessary to the germination of the germ, and thus the germination of the seed is accelerated.

The present invention relates to stable liquid formulations of ketoprofen, amitriptyline, and oxymetazoline.

A medicine for nourishing heart and relieving mental strain is prepared from 11 Chinese-medicinal materials including rhubarb, bupleurum root, white peony root, etc and 7 western medicines including amitriptyline, alprozolam, sulphiride, etc.

The present invention relates to pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents selected from the group consisting of analgesic acting substances, especially pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents selected from the group consisting of gabapentin, pregabalin, XP13512, carbamacepin, amitryptilin, ketorolac, diclofenac, ibuprofen, flurpirtin, paracetamol and dexamethasone, the process for their preparation and their use for the treatment and prevention of conditions and diseases selected from the group consisting of pain conditions of neuropathic origin.

The invention discloses a western medicine composition for treating liver cirrhosis, and the western medicine composition comprises the following main raw materials by weight: 20-35 parts of ademetionine, 35-45 parts of glucuronolactone, 4-8 parts of harmol, 17-22 parts of vasicinone, 4-9 parts of notoginsenoside R2, 1-4 parts of baicalein-7-methyl ether, 1-4 parts of Bavachinin A, 7-13 parts of Lucidin, 8-15 parts of oryzanol and 2-6 parts of amitriptyline. The raw materials of the western medicine composition for treating liver cirrhosis are strictly selected according to the understanding of the mechanism of the liver cirrhosis, the purpose of comprehensive rehabilitation can be achieved, and the western medicine composition has the characteristics of quick in effect, stable in effect, convenient to use and carry, and no toxic and side effects after long-term use.

The invention relates to the field of plant disease control, in particular to application of amitriptyline as a bactericide synergist in plant disease control. The occurrence of oomycete disease resistance to fungicides and even multi-drug resistance in the field is reported, resistance including an uncoupling agent is often associated with the multi-drug resistance, the management of such resistant groups is very difficult, and great harm is brought to agricultural production. According to the application of amitriptyline as the bactericide synergist in plant disease control, the amitriptyline and a diarylamine bactericide, substituted benzene bactericides or piperidinothiazole isoxazoline bactericides, are found to have good synergism on the combined toxicity of phytophthora resistant mutants after being mixed, the toxicity of the bactericides can be effectively improved, the sensitivity of drug resistant strains to the bactericides is restored, the usage amount of the bactericides is reduced, and a new method is provided for the development and application of new preparations of existing bactericides. The application provides a new application of farm chemical, can be used for disease control in the agricultural field, and provides a new way for disease resistance management in the field.

A medicinal composition is prepared from gentamycin, amitriptyline, honey, and 11 Chinese-medicinal materials including notoginseng, peach kernel, fennel, borax, etc. Its preparing process is also disclosed.

The invention provides a 25mg amitriptyline thin-film coating tablet prescription and a technological procedure, and relates to the technical field of medicines. The 25mg amitriptyline thin-film coating tablet prescription is prepared from the following components in parts by weight: tablet cores: 85.49 parts of hydryoxyapetite, 1.84 parts of corn starch, 15.56 parts of purified water, 25 parts ofamitriptyline hydrochloride, 6 parts of lactose, 9.9 parts of corn starch, 6.5 parts of microcrystalline celluloses, 1.3 parts of anhydrous silica gel, 1 part of stearic acid and 0.5 part of magnesium stearate; and a coating: 5.54 parts of coating powder, 30 parts of isopropanol and 30 parts of purified water. The technological procedure comprises the steps of granulating a prepared granulating solution, drying, sieving and meshing; dry-method granulating; totally mixing, and tabletting to form table cores; and preheating the tablet cores, processing the coating and drying. The bitter taste is adjusted through the corn starch, the color of the outer surface is improved through the coating, the mood of a patient is improved favorably, by the anhydrous silica gel, the 25mg amitriptyline thin-film coating tablet prescription is easily decomposed and absorbed, and health of the patient is facilitated.

The invention belongs to the technical field of medicine, and particularly discloses a medicine treating hemicranias and a preparation method thereof. The medicine comprises the following raw materials in parts by weight: 10 to 50 parts of naproxen, 10 to 20 parts of amitriptyline, 5 to 15 parts of povidone, 2 to 8 parts of calcium carboxymethylcellulose, 0.1 to 1 part of stearic acid, 0.1 to 0.5part of saccharose, 0.1 to 0.5 part of sulfite, 2 to 5 parts of methylcellulose, and 2 to 5 parts of cellulose acetate phthalate. The medicine selects clinically common single-dosage drugs as raw materials, the maximum content of each component does not exceed that in the regulations of a pharmacopeia, the medicine is safe to use and scientific in formula, does not have obvious side effect, and islow in cost.

The invention relates to a method for removing an anti-depressive drug, namely amitriptyline, in a water body. The method disclosed by the invention aims to solve the problems that the existing method for removing the anti-depressive drug in the water body is higher in cost, poor in removing rate and inconvenient to use. The method comprises the following steps: adding a ferrous salt solution into a pre-treated water body containing amitriptyline, adjusting the pH value of the water body to be about 3.5, then, adding hydrogen peroxide, and irradiating by adopting an ultraviolet high-pressure mercury lamp after uniformly mixing. The method disclosed by the invention has the advantages that amitriptyline is finally degraded into a substance, which can be used as a medical intermediate, so that secondary pollution cannot be caused; the method is rapid in reaction rate, high in degrading efficiency, simple and easy to operate and moderate in reaction condition; reaction reagents (sulphite and hydrogen peroxide) are low in cost and easy to obtain; and the method disclosed by the invention can be used for removing residual amitriptyline in the water body.

The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (notably neuropathic pain, neurodegenerative disorders, ischemic brain injury and inflammatory intestinal conditions). Additionally, the invention provides a method to enhance the therapeutic effect of amitriptyline for its common indications. The method of the invention involves combining amitriptyline with another HC-blocking agent, mefloquine.

Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.

A composition comprising at least one TCA or SSRI useful in a method for preventing or treating a skin disorder such as radiation dermatitis, and method of preventing, ameliorating, or treating the skin disorder by administering an effective amount of the TCA, e.g., amitriptyline or the SSRI, e.g., sertraline.

The invention belongs to the field of tumor medicines, in particular to application of amitriptyline to the preparation of medicines for treating multiple myeloma. The amitriptyline can not only treat the depression of a patient, but also can effectively control the proliferation of myeloma cells and induce the apoptosis of the myeloma cells. Meanwhile, the amitriptyline inducing the apoptosis of the myeloma cells has synergistic effect with dexamethasone, the synergistic effect of the amitriptyline and the dexamethasone is improved by 20-30 percent compared with single molecule treatment.

The invention discloses an application of amitriptyline to preparation of a medicine for improving endothelial cell functions, and belongs to the field of medicines. The medicine for improving the endothelial cell functions comprises any one of the following medicines: a medicine for promoting eNOS phosphorylation and NO release in endothelial cells, a medicine for inhibiting an endothelial cell inflammatory response induced by TNF-alpha, a medicine for inhibiting generation of endothelial cell active oxygen induced by TNF-alpha, and a medicine for relieving endothelial cell inflammation by inhibiting an MAPK signal channel and activation of NF-kappa B. The invention discloses and points out an action mechanism of the amitriptyline in vascular endothelial injury and inflammatory response for the first time, and tests verify that the amitriptyline can inhibit the vascular endothelial injury and the inflammatory response so as to improve endothelial cell functions. The amitriptyline has a good application prospect for preventing cardiovascular diseases caused by endothelial cell inflammation and endothelial cell dysfunction, and opens up a new medical approach for preventing and treating cardiovascular diseases.

The present invention describes a pharmaceutical composition at a fixed dose of paracetamol and specifically amitriptyline supported by the pharmacological interaction and safety studies that show its synergy for the anti-allodynic, the mechanical anti-hypernociceptive effects and for the reduction of persistent pain, proportions, safety and neuroprotective capacity. This is aimed to the treatment of mixed pain due to cancer that can be incorporated as another option in the strategy of the WHO analgesic ladder at step 1 for the treatment of mild pain. However, it can also be included in higher steps associated with opioids for the treatment of pain of greater intensity and potentially decrease the escalation of its doses and adverse effects such as tolerance and hyperalgesia.